A5071601553- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- Hepatocellular Carcinoma Treatment and Prognosis
- PI3K/AKT/mTOR signaling in cancer
- Cervical Cancer and HPV Research
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Cancer Mechanisms and Therapy
- Lymphoma Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Telomeres, Telomerase, and Senescence
- Thyroid Cancer Diagnosis and Treatment
- Endometriosis Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Microfluidic and Bio-sensing Technologies
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2015-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2015-2024
Pfizer (United Kingdom)
2023
Roche (Switzerland)
2023
Novartis (Switzerland)
2023
Jazz Pharmaceuticals (United States)
2023
Istituto Oncologico Romagnolo
2013
Abstract Purpose: To analyze the impact of TP53 mutations on response to first-line tyrosine kinase inhibitors (TKI) in patients with EGFR-mutated non–small cell lung cancer (NSCLC). Experimental Design: 136 NSCLC receiving TKIs were analyzed. evaluated 123 relation disease control rate (DCR), objective (ORR), progression-free survival (PFS), and overall (OS). Results: observed 37 (30.1%), 10 (27.0%), 6 (16.2%), 9 (24.3%), 12 (32.4%) exons 5, 6, 7, 8, respectively. DCR was 70% TP53-mutated...
Background: Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related deaths worldwide. Epidermal Growth Factor Receptor (EGFR)-mutated patients usually benefit from TKIs treatment, but a significant portion show unresponsiveness due to resistance mechanisms. We investigated role TP53 mutations in predicting survival and response EGFR-TKIs EGFR-mutated NSCLC patients, confirm, on an independent case series, our previous results. Methods: An retrospective cohort study was...
Sorafenib is a multi-targeted kinase inhibitor with demonstrated activity in renal cell carcinoma (RCC) and hepatocellular (HCC), it currently used for the treatment of these pathologies. Ongoing clinical trials are studying its other malignancies, such as non-small-cell lung cancer (NSCLC). However, no biological marker known to define either sensitivity or resistance drug. Here we report case patient two synchronous tumors, HCC NSCLC, metastases contralateral bone. The was treated...
There is evidence of a different response to treatment with regard the primary tumor localization (right-sided or left-sided) in patients metastatic colorectal cancer (mCRC). We analyzed outcomes and biomolecular characteristics relation 122 370 enrolled onto phase III prospective multicenter “Italian Trial Advanced Colorectal Cancer (ITACa)”, randomized receive first-line chemotherapy (CT) CT plus bevacizumab (CT + B). RAS BRAF mutations; baseline expression levels circulating vascular...
KRAS mutations negatively affect outcome after treatment with cetuximab in metastatic colorectal cancer (mCRC) patients. As only 20% of wild type (WT) patients respond to it is possible that other mutations, constitutively activating the EGFR pathway, are present non-responding WT We retrospectively analyzed objective tumor response rate, (ORR) progression-free (PFS) and overall survival (OS) respect mutational status KRAS, BRAF, PIK3CA PTEN expression mCRC treated a cetuximab-based...
Tyrosine kinase inhibitors (TKIs) are very efficacious in non-small-cell lung cancer (NSCLC) patients harboring activating Epidermal Growth Factor Receptor (EGFR) mutations. However, about 10% of EGFR wild type (wt) respond to TKI, with unknown molecular mechanisms sensitivity. We considered a case series 34 wt NSCLC responsive erlotinib after at least one line therapy. Responsive were matched an equal number non-responsive patients. A panel 26 genes, for total 214 somatic mutations, was...
Circulating tumor DNA predicts prognosis of mCRC patients receiving first-line bevacizumab based-chemotherapy
Biomarker testing is mandatory for the clinical management of patients with advanced non-small cell lung cancer (NSCLC). Myriads technical platforms are now available biomarker analysis differences in terms multiplexing capability, analytical sensitivity, and turnaround time (TAT). We evaluated performance diagnostic workflows 24 representative Italian institutions performing molecular tests on a series artificial reference specimens built to mimic routine samples. Sample sets eight slides...
Although fine needle aspiration (FNA) is the standard diagnostic test for characterization of a suspicious thyroid nodule, in some cases cytological evaluation inconclusive. The aim this study was to determine role BRAF mutation aiding diagnosis and verify whether archival samples could be suitable molecular analysis.Eighty-five patients with (Thy4) or follicular (Thy3) lesions on cytology were resubmitted second FNA analysis. Of these, 56 subsequently underwent surgery. usefulness analysis...
The identification of the mutations that drive lung cancer have furnished new targets for treatment non-small cell (NSCLC) and led to development targeted therapies such as tyrosine kinase inhibitors are used combat molecular changes promoting progression. Furthermore, biomarkers identified from gene analysis can be detect early cancer, determine patient prognosis, monitor response therapy. In present study we analyzed profile seventy-three Tunisian patients with adenocarcinoma (LAD)....
Liquid biopsy analysis for EGFR detection in cell-free DNA (cfDNA) from NSCLC patients has become routine. The aim of this study was to explore its applicability clinical practice.We collected data EGFR-mutated with liquid analysis. Data included test timing, concomitant tissue re-biopsy, therapy change, histology, stage, smoking habits, gender and age. All analyses were performed via a real-time PCR method analyze mutations at exons 18, 19, 20 21. Variant allele frequency available...
Endometriosis is a benign condition characterized by the presence of ectopic endometrial tissue. It still debated whether endometriosis disease that can predispose to pathogenesis cancer outside uterus. Deficiencies in mismatch repair (MMR) genes are known risk factor for developing endometrioid cancer. Starting from two cases patients with abnormal MMR carcinoma uterus and synchronous non-ovarian ovarian endometriosis, we performed somatic mutation profile phylogenetic analysis lesions...
The efficacy and cost-effectivness of Multigene Panel Next-Generation Sequencing (NGS) in directing patients towards genomically matched therapies remains uncertain. This study investigated metastatic colorectal cancer (mCRC) who underwent NGS analysis on formalin-fixed paraffin-embedded tumor samples. Data from 179 were analyzed, revealing no mutations 39 (21.8%), one mutation 83 (46.4%), two or more 57 (31.8%). KRAS found 87 (48.6%), including G12C 5 (2.8%), PIK3CA 40 (22.4%), BRAF 26...
Tyrosine kinase inhibitors (TKIs) and anti-anaplastic lymphoma (ALK) agents are highly effective for the treatment of non-small cell lung cancer (NSCLC) patients harbouring specific alterations, molecular characterisation tumour is needed even when limited material available.20 with a known epidermal growth factor receptor (EGFR) gene status were enrolled: 10 had mutated wild type tumours. FISH analysis was performed on one cytological or histological sample to determine EML4-ALK status,...
Analysis of circulating cell-free tumor DNA (cftDNA) has emerged as a specific and sensitive blood-based approach to detect epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients. Still, there is some debate on what should be the preferential clinical method for plasma-derived cftDNA analysis. We tested 31 NSCLC patients treated with anti-EGFR tyrosine kinase inhibitors (TKIs), at baseline serially during therapy, by comparing three methodologies...
The mutational status of the epidermal growth factor receptor ( EGFR ) guides stratification non‐small cell lung cancer (NSCLC) patients for treatment with tyrosine kinase inhibitors (TKIs). A liquid biopsy test on cell‐free DNA is recommended as a clinical decision‐supporting tool, although it has limited sensitivity. Here, we comparatively investigated extracellular vesicle (EV)‐RNA an independent source multidimensional and longitudinal profiling in cohort 27 NSCLC patients. We introduced...
Objectives Amplification of human telomerase is known to be associated with cervical tumorigenesis, although its role in tumor progression lesions still unclear. We aimed evaluate the predicting evolution lesions. Methods A total 50 tissue samples taken by biopsy or conization once repeatedly from 17 patients over a 14-year follow-up was analyzed using fluorescence situ hybridization (FISH) for hTERC gene alterations and immunohistochemistry (IHC) hTERT expression. The accuracy biomarkers...
Neuroendocrine neoplasms (NENs) are a rare group of tumors exceptionally heterogeneous, with clinical presentation ranging from well differentiated more indolent to poorly very aggressive forms. Both often diagnosed after the metastatic spread and require appropriate medical treatment. A high priority need in management this disease is identification effective therapeutic strategies for advanced patients. The recent TALENT trial demonstrated efficacy lenvatinib, multi-tyrosine kinase...
9052 Background: Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations are usually responsive to tyrosine kinase inhibitors (TKIs). However, about 20% of EGFR-mutated patients resistant TKIs. We analyzed the impact TP53 on response first-line TKI treatment in NSCLC patients. Methods: 123 receiving a were analyzed. The different evaluated relation disease control rate (DCR: complete [CR] + partial [PR] stable [SD]), progression-free...